Suppressive efficiency of RASSF1A in endometrial carcinoma via inhabiting estrogen receptor alpha expression and ERK pathway activation
Fangfang Nan1, Shuangyan Wei1, Dongdong Guan1
1Department of Obstetrics and Gynaecology, Binzhou Medical University Hospital Binzhou 256603, Shandong Province, China.
Introduction:
Known as a tumor suppressor, the Ras association domain family 1 isoform A (RASSF1A) is implicated in many human cancers, such as endometrial carcinoma. There is little known about the tumor inhibitive effects of RASSF1A on endometrial carcinoma. The present study was designed to investigate the role of RASSF1A in HEC-1-A cells and to explore its potential mechanisms.
Materials And Methods:
In this study, overexpression of RASSF1A was established by transfection the recombinant adenoviral RASSF1A in HEC-1-A cells. Cells viability was assessed by MTT assay and the apoptosis was analyzed using flow cytometry. Cell migration and invasion were measured in Transwell assay. The levels of ERα and PELP1 protein and extracellular regulated protein kinase (ERK) pathway activation were detected by Western blot.
Results:
RASSF1A over-expression could significantly inhibit the proliferation, migration and invasion of the HEC-1-A cells in transfection with RASSF1A group compared to that in transfection with control group, also induced apoptosis and suppressed the tumor growth after injection in nude mice. Moreover, overexpression of RASSF1A could inhibit the ERK signal pathway activation and decrease the ERα and PELP1 expression.
Conclusion:
Tumor suppressive efficiency of RASSF1A is exerted through the regulation of ERK pathway activation, ERα and PELP1 expression.
Insights
Ras association domain family 1 isoform A (RASSF1A) suppresses endometrial carcinoma growth by inhibiting proliferation, migration, and invasion. RASSF1A targets the ERK pathway and reduces ERα and PELP1 expression, highlighting its tumor-suppressive role.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Ras association domain family 1 isoform A (RASSF1A) is a known tumor suppressor involved in various human cancers.
- Its specific role and mechanisms in endometrial carcinoma remain largely unexplored.
Purpose of the Study:
- To investigate the tumor-inhibitive effects of RASSF1A in endometrial carcinoma.
- To elucidate the underlying molecular mechanisms of RASSF1A's action in HEC-1-A cells.
Main Methods:
- Overexpression of RASSF1A in HEC-1-A cells via adenoviral transfection.
- Assessment of cell viability (MTT assay), apoptosis (flow cytometry), migration/invasion (Transwell assay).
- Western blot analysis for ERα, PELP1 protein levels, and ERK pathway activation.
Main Results:
- RASSF1A overexpression significantly inhibited HEC-1-A cell proliferation, migration, and invasion.
- RASSF1A induced apoptosis and suppressed tumor growth in vivo (nude mice).
- Overexpression of RASSF1A led to decreased ERK pathway activation and reduced ERα and PELP1 expression.
Conclusions:
- RASSF1A exhibits significant tumor-suppressive effects in endometrial carcinoma.
- These effects are mediated through the inhibition of the ERK signaling pathway.
- RASSF1A also regulates the expression of ERα and PELP1, contributing to its tumor-suppressive function.
